C4 Therapeutics, Inc. (CCCC)
Business numbers score is below the middle, with price trend score is below the middle.
CCCC scores higher than 63% of the 1,101 tickers we compare it with (Health Care).
As of 9 October 2026, C4 Therapeutics, Inc. (CCCC) scores 47 out of 100 on the Market Census six-factor composite, which puts it at the Average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 9 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 1.19× 30-day average
- 52-week range
- 1.69 – 5.17
- Market cap
- $417.06M
- Earnings date
- 4 Nov 2026
- Volume
- 2,506,053
- Avg. volume (30d)
- 2,106,212
- Open
- 3.00
- Previous close
- 2.85
- Day's range (regular session)
- 2.95 – 3.19
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- 3.17
- P/E (TTM)
- —
- EPS (TTM)
- -1.00
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
Premium data held for CCCC
- 4 SEC Form 4 insider transactions in the last 90 daysPremium
Counts of rows Market Census holds for CCCC. A dash in the factor table above means that factor has no data for this ticker — it is not a locked value. Compare plans
What the score says about CCCC right now
C4 Therapeutics, Inc. (CCCC) currently scores 47/100 on the Market Census six-factor composite, at the Average score level. CCCC is +10.88% on the day and +6.95% over five sessions as of the most recent tick. Average sits in the middle. The good and the bad in CCCC's data roughly balance out right now. CCCC's strongest factor is insider trades at 69/100 — a strong read on insider buying and selling. Insider filings currently lean toward buying on this name — a plain read of public filings, not a signal to follow. The weakest factor is company finances at 18/100 — well below average company numbers. A low company-finances reading is the canonical "value trap" warning: technical setups on broken fundamentals don't tend to compound.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See CCCC in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent CCCC news
Latest headlines that name C4 Therapeutics, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual MeetingGlobeNewswire Inc.
- C4 Therapeutics Presents New Biomarker Data From Phase 1 Clinical Trial Of Cemsidomide In Combination With Dexamethasone In Patients With RRMM At 23rd IMS Annual MeetingBenzinga
- Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?Yahoo
- C4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide ReadoutsSeekingAlpha
- C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual MeetingYahoo
We hide 1 more that told readers to buy or sell, or gave a price target.
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to CCCC’s 47, all within 1 point.
Sorted by closeness to CCCC’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.